PellePharm's Topical Patidegib Nears Phase III For Gorlin Syndrome
Gel formulations of the hedgehog signalling inhibitor patidegib may be the long sought well-tolerated and effective therapy for basal cell carcinoma and the rare disease, Gorlin syndrome.
You may also be interested in...
Emerging Company Profile: With backing from BridgeBio, San Francisco start-up QED sees potential for drug licensed from Novartis in a number of tumor types, following the recent presentation of promising results in Phase II for bile duct cancer and Phase I for advanced urothelial cancer.
BridgeBio's hub-and-spoke model is similar to the Roivant and Fortress strategies, but with a focus on drug candidates for genetic diseases in need of a bridge to future funding.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.